Recent advances in systemic therapy for hepatocellular carcinoma
H Zhang, W Zhang, L Jiang, Y Chen - Biomarker Research, 2022 - Springer
Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumors in
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
the world. Therapeutic options for advanced HCC are limited. Systemic treatment, especially …
Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand?
A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …
worldwide, still representing an important cause of cancer-related death. Over the next few …
[HTML][HTML] Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score
B Scheiner, K Pomej, MM Kirstein, F Hucke… - Journal of …, 2022 - Elsevier
Background & Aims Immunotherapy with atezolizumab plus bevacizumab represents the
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …
new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC) …
[HTML][HTML] Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in …
Single-cell RNA-sequencing (scRNA-seq) presents better insights into cell behavior in the
context of a complex tumor microenvironment by profiling single-cell populations. However …
context of a complex tumor microenvironment by profiling single-cell populations. However …
ZnS@ BSA nanoclusters potentiate efficacy of cancer immunotherapy
D Cen, Q Ge, C Xie, Q Zheng, J Guo… - Advanced …, 2021 - Wiley Online Library
Although immunotherapy such as immune checkpoint inhibitors has shown promising
efficacy in cancer treatment, the responsiveness among patients is relatively limited …
efficacy in cancer treatment, the responsiveness among patients is relatively limited …
Transarterial chemoembolization with PD-(L) 1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
HD Zhu, HL Li, MS Huang, WZ Yang, GW Yin… - Signal transduction and …, 2023 - nature.com
There is considerable potential for integrating transarterial chemoembolization (TACE),
programmed death-(ligand) 1 (PD-[L] 1) inhibitors, and molecular targeted treatments (MTT) …
programmed death-(ligand) 1 (PD-[L] 1) inhibitors, and molecular targeted treatments (MTT) …
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses
B Zuo, Y Zhang, K Zhao, L Wu, H Qi, R Yang… - Journal of hematology & …, 2022 - Springer
Background Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of
individual patients holds promise for tumors with high genetic heterogeneity, potentially …
individual patients holds promise for tumors with high genetic heterogeneity, potentially …
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
A Rizzo, A Cusmai, G Gadaleta-Caldarola… - Expert review of …, 2022 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …
worldwide, still representing an important cause of cancer-related death. Recent years have …
First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges
A Rizzo, AD Ricci, G Gadaleta-Caldarola… - Expert Review of …, 2021 - Taylor & Francis
Introduction Immunotherapy has recently taken on an extremely important role in medical
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
oncology, as first-or later-line treatment in several tumor types, and recent years have seen …
NASH and hepatocellular carcinoma: immunology and immunotherapy
The last 10 years have revolutionized our basic understanding of nonalcoholic fatty liver
disease and consequent liver cancer. It has become clear that several innate and adaptive …
disease and consequent liver cancer. It has become clear that several innate and adaptive …